Parkinson's disease: clinical subtyping can help estimate course, survival

  • JAMA Neurol

  • curated by Susan London
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • 3 subtypes of Parkinson's disease evident at diagnosis are associated with disease course and survival.

Why this matters

  • Persistent difficulty in accurately estimating prognosis.

Key results

  • 3 subtypes identified:
    • Mild-motor predominant (48.7% of patients).
    • Intermediate (35.1% of patients).
    • Diffuse malignant (16.2% of patients).
  • Graded associations seen for earlier milestone development, shorter survival.
  • Diffuse malignant subtype independently predicted:
    • Any disease milestone (aHR, 10.90; P<.001>
    • Death (aHR, 3.65; P<.001>
  • Smaller significant elevations of risk also seen for intermediate subtype.
  • Only other variable independently predicting outcomes was age at diagnosis:
    • Any disease milestone (aHR, 1.09; P<.001>
    • Death (aHR, 1.14; P<.001>
  • Subtypes did not differ on staging of Lewy pathology, Alzheimer's disease-related pathology.

Study design

  • UK retrospective cohort study: 111 consecutive patients with autopsy-confirmed Parkinson's disease regularly seen throughout their disease course, having brain autopsy.
  • Subtypes defined on 4 factors at diagnosis: motor symptom severity, rapid eye movement sleep behavior disorder, autonomic function, cognitive function.
  • Main outcomes: time to disease milestones (recurrent falls, wheelchair dependence, dementia, care home placement), survival.
  • Funding: National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Limitations

  • Variations in patient assessment.
  • Patients predominantly had advanced clinical, pathologic stages.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit